Japanese Encephalitis Immunity & Severe Dengue Illness
- Scientists have discovered a concerning link between declining immunity to Japanese encephalitis virus (JEV) and an increased risk of severe dengue fever. A study conducted by researchers at...
- Both Japanese encephalitis and dengue are significant public health threats, notably in Asia.Japanese encephalitis, transmitted by mosquitoes, causes severe neurological illness in approximately 25% of those affected, often...
- Both viruses belong to the Flaviviridae family, meaning they share structural similarities.
waning Japanese Encephalitis Immunity Linked to More Severe Dengue Fever
Table of Contents
- waning Japanese Encephalitis Immunity Linked to More Severe Dengue Fever
- At a Glance
- Understanding the Viruses: JEV and Dengue
- The Nepal Study: A Unique Opportunity
- Antibody-Mediated Enhancement: A Dangerous Backfire
- Measuring Disease Severity: The Role of Chymase
- Implications for public Health and Vaccination Strategies
- the Bigger Picture: JEV vs. Dengue and Future Research
- Editor’s Analysis
- Funding and Source Information
Scientists have discovered a concerning link between declining immunity to Japanese encephalitis virus (JEV) and an increased risk of severe dengue fever. A study conducted by researchers at Duke-NUS Medical School, in collaboration with colleagues in Nepal, reveals that individuals previously vaccinated against JEV, but with waning antibody levels, are more susceptible to experiencing severe symptoms when infected with dengue. The findings, published in Science Translational Medicine, highlight the complex interplay between immunity to related viruses and the potential for unintended consequences of vaccination strategies.
Understanding the Viruses: JEV and Dengue
Both Japanese encephalitis and dengue are significant public health threats, notably in Asia.Japanese encephalitis, transmitted by mosquitoes, causes severe neurological illness in approximately 25% of those affected, often leading to long-term disability or death. Effective vaccination programs have made substantial progress in controlling JEV in countries like Nepal. Dengue fever,also mosquito-borne,is the fastest-growing viral disease globally,with cases rapidly increasing,especially in Nepal. While there are dengue vaccines, prevention largely relies on mosquito control and personal protective measures.
Both viruses belong to the Flaviviridae family, meaning they share structural similarities. This shared ancestry is key to understanding the observed immune interaction.
| Virus | Transmission | Severity | Prevention |
|---|---|---|---|
| Japanese Encephalitis Virus (JEV) | Mosquitoes (Culex species) | Severe neurological illness (25% mortality, long-term disability) | Vaccination (highly effective) |
| Dengue Virus (DENV) | Mosquitoes (Aedes species) | Wide spectrum, from mild fever to severe hemorrhagic fever and shock syndrome | Mosquito control, personal protection, vaccines (limited availability/efficacy) |
The Nepal Study: A Unique Opportunity
The research team strategically chose Nepal as the study location due to its unique epidemiological profile. Nepal is one of the few countries experiencing a rapid increase in dengue cases within a population already possessing widespread immunity to JEV through vaccination. This allowed researchers to directly observe how prior JEV immunity influenced the severity of dengue illness.
“we chose Nepal as a study site as it’s one of the few countries where dengue is spreading quickly in a population that already has widespread immunity to another flavivirus, Japanese encephalitis. This gave us a unique chance to see how prior immunity shapes dengue illness, and we found that people whose Japanese encephalitis immunity had waned were more likely to become severely ill from dengue.”
– Dr. Sidharth Malhotra, Program in Emerging infectious Diseases, Duke-NUS Medical School
The study involved analyzing data from over 500 patients over a five-year period. Researchers found a clear correlation: individuals with declining JEV antibody levels were substantially more likely to develop severe dengue symptoms compared to those with robust JEV immunity.
Antibody-Mediated Enhancement: A Dangerous Backfire
The underlying mechanism driving this phenomenon appears to be antibody-mediated enhancement (ADE)
. This occurs when antibodies generated from a previous infection or vaccination aren’t strong enough to neutralize a new virus but still bind to it. Instead of providing protection, these partially effective antibodies can actually facilitate viral entry into immune cells, accelerating viral replication and triggering an exaggerated immune response. This heightened immune response leads to increased inflammation and more severe disease.
While ADE is well-documented in the context of multiple dengue infections (secondary infection with a different serotype),this study demonstrates that it can also occur when immunity to a related virus,like JEV,diminishes. This expands our understanding of how cross-reactive immunity can impact health outcomes.
Measuring Disease Severity: The Role of Chymase
To assess the severity of dengue illness, the researchers measured levels of chymase, an enzyme released during inflammation and associated with more serious disease progression. They discovered significantly higher chymase levels in patients with moderate JEV antibody levels. These individuals also exhibited warning signs of severe dengue, including bleeding, abdominal pain, and fluid leakage – indicators of potential progression to dengue shock syndrome.
Implications for public Health and Vaccination Strategies
The findings have significant implications for public health strategies in regions where both JEV and dengue are endemic. Associate Professor Ashley St John emphasizes the need to maintain strong JEV protection through timely booster shots, not only to prevent Japanese encephalitis but also to reduce the risk of severe dengue.
“This discovery matters for countries like Nepal and across Asia where both viruses circulate. It also highlights the need to keep JEV protection strong, through well-timed booster shots, not only to prevent Japanese Encephalitis itself but also to reduce the risk of severe dengue.” – Associate Professor Ashley St John, Duke-NUS Medical School
This knowledge could benefit millions of people living in affected areas, including travelers requiring JEV vaccination. Strengthening JEV vaccination programs and considering booster doses could offer a practical approach to mitigating the risk of severe dengue.
The study’s relevance is heightened by the increasing spread of mosquito-borne diseases due to climate change and urbanization. Nepal has experienced a dramatic rise in dengue cases in recent years, even in areas previously unaffected. changing weather patterns and expanding mosquito habitats are contributing to this expansion.
the Bigger Picture: JEV vs. Dengue and Future Research
Professor Patrick Tan highlights the relative burden of the two diseases: while dengue is often less deadly, Japanese encephalitis is a more devastating illness that can be largely prevented through vaccination. Therefore, strengthening JEV vaccination programs offers a double benefit – preventing JEV and potentially reducing the severity of dengue.
The research team is continuing to monitor dengue evolution in the region, particularly as new viral strains emerge and the population’s immune landscape becomes more complex. They are also collaborating with partners to develop optimal vaccination strategies to protect communities against dengue and related viral infections.
Funding and Source Information
This study was supported by the SingHealth Duke-NUS Global Health Institute and the Singapore Ministry of Education.